The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CINV Existing and Pipeline Drugs Market Research Report 2024
Synopsis
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global CINV Existing and Pipeline Drugs market was valued at US$ 1518.2 million in 2023 and is anticipated to reach US$ 1954.9 million by 2030, witnessing a CAGR of 3.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CINV Existing and Pipeline Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CINV Existing and Pipeline Drugs.
Report Scope
The CINV Existing and Pipeline Drugs market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CINV Existing and Pipeline Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CINV Existing and Pipeline Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Segment by Type
Aloxi
Zofran Generic
Kytril Generic
Emend
Akynzeo
SUSTOL
Rolapitant
Segment by Application
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of CINV Existing and Pipeline Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global CINV Existing and Pipeline Drugs market was valued at US$ 1518.2 million in 2023 and is anticipated to reach US$ 1954.9 million by 2030, witnessing a CAGR of 3.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CINV Existing and Pipeline Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CINV Existing and Pipeline Drugs.
Report Scope
The CINV Existing and Pipeline Drugs market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CINV Existing and Pipeline Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CINV Existing and Pipeline Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Segment by Type
Aloxi
Zofran Generic
Kytril Generic
Emend
Akynzeo
SUSTOL
Rolapitant
Segment by Application
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of CINV Existing and Pipeline Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 CINV Existing and Pipeline Drugs Market Overview
1.1 Product Overview and Scope of CINV Existing and Pipeline Drugs
1.2 CINV Existing and Pipeline Drugs Segment by Type
1.2.1 Global CINV Existing and Pipeline Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Aloxi
1.2.3 Zofran Generic
1.2.4 Kytril Generic
1.2.5 Emend
1.2.6 Akynzeo
1.2.7 SUSTOL
1.2.8 Rolapitant
1.3 CINV Existing and Pipeline Drugs Segment by Application
1.3.1 Global CINV Existing and Pipeline Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Diagnostic Centers Therapeutics
1.3.5 Hospital Pharmacies
1.3.6 Drugstores
1.4 Global CINV Existing and Pipeline Drugs Market Size Estimates and Forecasts
1.4.1 Global CINV Existing and Pipeline Drugs Revenue 2019-2030
1.4.2 Global CINV Existing and Pipeline Drugs Sales 2019-2030
1.4.3 Global CINV Existing and Pipeline Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 CINV Existing and Pipeline Drugs Market Competition by Manufacturers
2.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global CINV Existing and Pipeline Drugs Average Price by Manufacturers (2019-2024)
2.4 Global CINV Existing and Pipeline Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Product Type & Application
2.7 CINV Existing and Pipeline Drugs Market Competitive Situation and Trends
2.7.1 CINV Existing and Pipeline Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest CINV Existing and Pipeline Drugs Players Market Share by Revenue
2.7.3 Global CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 CINV Existing and Pipeline Drugs Retrospective Market Scenario by Region
3.1 Global CINV Existing and Pipeline Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global CINV Existing and Pipeline Drugs Global CINV Existing and Pipeline Drugs Sales by Region: 2019-2030
3.2.1 Global CINV Existing and Pipeline Drugs Sales by Region: 2019-2024
3.2.2 Global CINV Existing and Pipeline Drugs Sales by Region: 2025-2030
3.3 Global CINV Existing and Pipeline Drugs Global CINV Existing and Pipeline Drugs Revenue by Region: 2019-2030
3.3.1 Global CINV Existing and Pipeline Drugs Revenue by Region: 2019-2024
3.3.2 Global CINV Existing and Pipeline Drugs Revenue by Region: 2025-2030
3.4 North America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.4.1 North America CINV Existing and Pipeline Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America CINV Existing and Pipeline Drugs Sales by Country (2019-2030)
3.4.3 North America CINV Existing and Pipeline Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.5.1 Europe CINV Existing and Pipeline Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe CINV Existing and Pipeline Drugs Sales by Country (2019-2030)
3.5.3 Europe CINV Existing and Pipeline Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific CINV Existing and Pipeline Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific CINV Existing and Pipeline Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific CINV Existing and Pipeline Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.7.1 Latin America CINV Existing and Pipeline Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America CINV Existing and Pipeline Drugs Sales by Country (2019-2030)
3.7.3 Latin America CINV Existing and Pipeline Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa CINV Existing and Pipeline Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global CINV Existing and Pipeline Drugs Sales by Type (2019-2030)
4.1.1 Global CINV Existing and Pipeline Drugs Sales by Type (2019-2024)
4.1.2 Global CINV Existing and Pipeline Drugs Sales by Type (2025-2030)
4.1.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2019-2030)
4.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2019-2030)
4.2.1 Global CINV Existing and Pipeline Drugs Revenue by Type (2019-2024)
4.2.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2025-2030)
4.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2019-2030)
4.3 Global CINV Existing and Pipeline Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global CINV Existing and Pipeline Drugs Sales by Application (2019-2030)
5.1.1 Global CINV Existing and Pipeline Drugs Sales by Application (2019-2024)
5.1.2 Global CINV Existing and Pipeline Drugs Sales by Application (2025-2030)
5.1.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2019-2030)
5.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2019-2030)
5.2.1 Global CINV Existing and Pipeline Drugs Revenue by Application (2019-2024)
5.2.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2025-2030)
5.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2019-2030)
5.3 Global CINV Existing and Pipeline Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Helsinn
6.2.1 Helsinn Corporation Information
6.2.2 Helsinn Description and Business Overview
6.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Helsinn CINV Existing and Pipeline Drugs Product Portfolio
6.2.5 Helsinn Recent Developments/Updates
6.3 Heron Therapeutics
6.3.1 Heron Therapeutics Corporation Information
6.3.2 Heron Therapeutics Description and Business Overview
6.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio
6.3.5 Heron Therapeutics Recent Developments/Updates
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck CINV Existing and Pipeline Drugs Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Tesaro
6.5.1 Tesaro Corporation Information
6.5.2 Tesaro Description and Business Overview
6.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Tesaro CINV Existing and Pipeline Drugs Product Portfolio
6.5.5 Tesaro Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 CINV Existing and Pipeline Drugs Industry Chain Analysis
7.2 CINV Existing and Pipeline Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 CINV Existing and Pipeline Drugs Production Mode & Process
7.4 CINV Existing and Pipeline Drugs Sales and Marketing
7.4.1 CINV Existing and Pipeline Drugs Sales Channels
7.4.2 CINV Existing and Pipeline Drugs Distributors
7.5 CINV Existing and Pipeline Drugs Customers
8 CINV Existing and Pipeline Drugs Market Dynamics
8.1 CINV Existing and Pipeline Drugs Industry Trends
8.2 CINV Existing and Pipeline Drugs Market Drivers
8.3 CINV Existing and Pipeline Drugs Market Challenges
8.4 CINV Existing and Pipeline Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
